FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078731091> ?p ?o ?g. }

• W2078731091 endingPage "S89" @default.
• W2078731091 startingPage "S83" @default.
• W2078731091 abstract "Anxiety is a major and frequent symptom of schizophrenia, which is associated with an increased risk of relapse, impaired functioning, lower quality of life and increased incidence of suicide attempts. Despite its clinical relevance, anxiety in schizophrenia remains poorly understood. In the prodromic phase, anxiety indicates a progression towards psychotic decompensation. After a first episode, it is an indicator of relapse.Two approaches have been used to investigate anxiety in schizophrenia: (i) categorical approach (comorbidity of schizophrenia and anxiety disorders) and (ii) dimensional approach (anxiety as a major symptom of the dysphoric dimension). Clinical categorical studies reported an increased frequency of comorbidity between schizophrenia and obsessive-compulsive disorder, panic disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, agoraphobia, and specific phobia. The dimensional approach proposes that five different factors contribute to the structure of the Positive and Negative Syndrome Scale (PANSS), with anxiety as a major symptom of the dysphoria dimension. Concerning diagnosis, it is unclear whether psychotic and neurotic anxiety differs in nature or intensity. Nevertheless, both are frequently opposed.Psychotic anxiety is intense, profound and hermetic. In contrast to neurotic anxiety, it is associated with psychomotor disturbances, such as agitation and sideration. There is no specific tool to evaluate anxiety in schizophrenia. The dimensional approach usually runs an evaluation using items or factors extracted from the most widely-used scales, i.e. PANSS or Brief Psychiatric Rating Scale (BPRS) or from anxiety scales developed in non-schizophrenic populations, such as the Hamilton Anxiety Scale (HAMA). Recently, we developed a specific scale for hetero-evaluation (Échelle Anxiété Schizophrénie [EAS scale]). The EAS scale was recently validated and the study of its sensitivity is ongoing. THERAPEUTICAL ISSUES: Several studies have examined the effects of antipsychotics on the anxious/depressive cluster extracted from the PANSS, and some other studies have specifically evaluated the effect of antipsychotics on depressive symptoms using the Montgomery and Asberg Depression Rating Scale (MADRS) and Calgary Depression Scale for Schizophrenia (CDSS), but to our knowledge, no study has reported the effect of antipsychotics or other treatment on anxiety when using a schizophrenia-specific scale. There are no specific guideline treatments for anxiety in schizophrenia. Among phenothiazines, cyamemazine is frequently prescribed in France, because of its potent anxiolytic activity and good neurological tolerance. Some authors have suggested a specific treatment with benzodiazepines. However, benzodiazepines should be used with caution, due to undesirable actions such as dependence, rebound and potentiation of certain lateral effects." @default.
• W2078731091 created "2016-06-24" @default.
• W2078731091 creator A5016407367 @default.
• W2078731091 creator A5020165832 @default.
• W2078731091 creator A5030038342 @default.
• W2078731091 creator A5036687562 @default.
• W2078731091 creator A5044155207 @default.
• W2078731091 creator A5049886953 @default.
• W2078731091 creator A5083894824 @default.
• W2078731091 creator A5089955461 @default.
• W2078731091 date "2011-05-01" @default.
• W2078731091 modified "2023-10-01" @default.
• W2078731091 title "Prise en charge médicamenteuse de l’anxiété chez le patient souffrant de schizophrénie" @default.
• W2078731091 cites W141022849 @default.
• W2078731091 cites W1457595327 @default.
• W2078731091 cites W1969922010 @default.
• W2078731091 cites W1970319007 @default.
• W2078731091 cites W1971479653 @default.
• W2078731091 cites W1973107264 @default.
• W2078731091 cites W1974734218 @default.
• W2078731091 cites W1977725618 @default.
• W2078731091 cites W1994481621 @default.
• W2078731091 cites W1994599653 @default.
• W2078731091 cites W2001515160 @default.
• W2078731091 cites W2002131648 @default.
• W2078731091 cites W2004956512 @default.
• W2078731091 cites W2006019396 @default.
• W2078731091 cites W2018016961 @default.
• W2078731091 cites W2019144775 @default.
• W2078731091 cites W2023815148 @default.
• W2078731091 cites W2024891385 @default.
• W2078731091 cites W2050393823 @default.
• W2078731091 cites W2051147886 @default.
• W2078731091 cites W2056310659 @default.
• W2078731091 cites W2078597036 @default.
• W2078731091 cites W2085346206 @default.
• W2078731091 cites W2088412248 @default.
• W2078731091 cites W2100233372 @default.
• W2078731091 cites W2102727430 @default.
• W2078731091 cites W2102784477 @default.
• W2078731091 cites W2105912052 @default.
• W2078731091 cites W2108327356 @default.
• W2078731091 cites W2116615757 @default.
• W2078731091 cites W2137959682 @default.
• W2078731091 cites W2149907201 @default.
• W2078731091 cites W2161667047 @default.
• W2078731091 cites W2170882469 @default.
• W2078731091 cites W2329066428 @default.
• W2078731091 cites W2331468866 @default.
• W2078731091 cites W4252834474 @default.
• W2078731091 doi "https://doi.org/10.1016/j.encep.2010.08.009" @default.
• W2078731091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21600338" @default.
• W2078731091 hasPublicationYear "2011" @default.
• W2078731091 type Work @default.
• W2078731091 sameAs 2078731091 @default.
• W2078731091 citedByCount "14" @default.
• W2078731091 countsByYear W20787310912013 @default.
• W2078731091 countsByYear W20787310912014 @default.
• W2078731091 countsByYear W20787310912015 @default.
• W2078731091 countsByYear W20787310912017 @default.
• W2078731091 countsByYear W20787310912018 @default.
• W2078731091 countsByYear W20787310912019 @default.
• W2078731091 countsByYear W20787310912020 @default.
• W2078731091 countsByYear W20787310912023 @default.
• W2078731091 crossrefType "journal-article" @default.
• W2078731091 hasAuthorship W2078731091A5016407367 @default.
• W2078731091 hasAuthorship W2078731091A5020165832 @default.
• W2078731091 hasAuthorship W2078731091A5030038342 @default.
• W2078731091 hasAuthorship W2078731091A5036687562 @default.
• W2078731091 hasAuthorship W2078731091A5044155207 @default.
• W2078731091 hasAuthorship W2078731091A5049886953 @default.
• W2078731091 hasAuthorship W2078731091A5083894824 @default.
• W2078731091 hasAuthorship W2078731091A5089955461 @default.
• W2078731091 hasConcept C118552586 @default.
• W2078731091 hasConcept C15744967 @default.
• W2078731091 hasConcept C187288502 @default.
• W2078731091 hasConcept C2776317618 @default.
• W2078731091 hasConcept C2776412080 @default.
• W2078731091 hasConcept C2777529043 @default.
• W2078731091 hasConcept C2777545354 @default.
• W2078731091 hasConcept C2778678127 @default.
• W2078731091 hasConcept C2779159551 @default.
• W2078731091 hasConcept C2779727114 @default.
• W2078731091 hasConcept C2779911313 @default.
• W2078731091 hasConcept C2780135775 @default.
• W2078731091 hasConcept C2780712732 @default.
• W2078731091 hasConcept C558461103 @default.
• W2078731091 hasConcept C70410870 @default.
• W2078731091 hasConcept C77805123 @default.
• W2078731091 hasConcept C94612546 @default.
• W2078731091 hasConceptScore W2078731091C118552586 @default.
• W2078731091 hasConceptScore W2078731091C15744967 @default.
• W2078731091 hasConceptScore W2078731091C187288502 @default.
• W2078731091 hasConceptScore W2078731091C2776317618 @default.
• W2078731091 hasConceptScore W2078731091C2776412080 @default.
• W2078731091 hasConceptScore W2078731091C2777529043 @default.
• W2078731091 hasConceptScore W2078731091C2777545354 @default.
• W2078731091 hasConceptScore W2078731091C2778678127 @default.

• next